Priothera Limited, which has only been in operation for just over two years, can start thinking about regulatory submissions for its acute myeloid leukemia (AML) therapy mocravimod now that a late-stage trial is underway.
Priothera Moves Mocravimod Into Pivotal Trials
High Hopes For Leukemia Therapy
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.
More from Anticancer
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.